Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: A simulation for the EU G5 countries

Future Oncology

Volumn 10, Issue 9, 2014, Pages 1599-1609

  Abraham, Ivo ^a,b,c   Han, Lucy ^b   Sun, Diana ^a   Macdonald, Karen ^c   Aapro, Matti ^d  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c Matrix45   (United States)

^d CLINIQUE DE GENOLIER   (Switzerland)

Author keywords

antineoplastic therapy; biosimiar; budgetary impact; cancer; chemotherapy induced anemia; epoetin alfa; EU; simulation

Indexed keywords

ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIOSIMILAR AGENT; EPOIETIN ALFA HEXAL; RECOMBINANT ERYTHROPOIETIN; RITUXIMAB; TRASTUZUMAB; UNCLASSIFIED DRUG; ERYTHROPOIETIN; MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN;

ARTICLE; BUDGET; CANCER PATIENT; CHEMOTHERAPY INDUCED ANEMIA; COST CONTROL; EUROPEAN UNION; HEALTH CARE ACCESS; HUMAN; PATIENT CARE; PRIORITY JOURNAL; SIMULATION; ANEMIA; CHEMICALLY INDUCED; DRUG COST; ECONOMICS; NEOPLASMS; STATISTICAL MODEL;

ANEMIA; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; BIOSIMILAR PHARMACEUTICALS; DRUG COSTS; ERYTHROPOIETIN; EUROPEAN UNION; HEMATINICS; HUMANS; MODELS, ECONOMIC; NEOPLASMS; RECOMBINANT PROTEINS;

EID: 84906572793     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.43     Document Type: Article

References (34)

1. Schellekens H. How similar do ?biosimilars' need to be? Nat. Biotechnol. 22(11), 1357-1359 (2004
2. Aapro M, Cornes P, Abraham I. Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia. J. Oncol. Pharm. Pract. 18(2), 171-179 (2012
3. Abraham I, MacDonald K. Clinical safety of biosimilar recombinant human erythropoietins. Exp. Opin. Drug Safe. 11(5), 819-840 (2012
4. Ebbers HC, Crow SA, Vulto AG et al. Interchangeability, immunogenicity and biosimilars. Nat. Biotechnol. 30(12), 1186-1190 (2012
5. Niederwieser D, Schmitz S. Biosimilar agents in oncology/haematology: from approval to practice. Euro. J. Haematol. 86(4), 277-288 (2011
6. Aapro MS. What do prescribers think of biosimilars? Target. Oncol. 7(Suppl. 1), S51-55 (2012
7. Schellekens H. Biosimilar therapeutics-what do we need to consider? NDT Plus 2(Suppl. 1), i27-i36 (2009
8. Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann. Oncol. 19(3), 411-419 (2008
9. Haag-Weber M, Vetter A, Thyroff-Friesinger U. Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis. Clin. Nephrol. 72(5), 380-390 (2009
10. Weigang-Kohler K, Vetter A, Thyroff-Friesinger U. HX575, recombinant human epoetin alfa, for the treatment of chemotherapy-associated symptomatic anaemia in patients with solid tumours. Onkologie 32(4), 168-174 (2009
11. Wizemann V, Rutkowski B, Baldamus C et al. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment. Curr. Med. Res. Opin. 24(3), 625-637 (2008
12. Krivoshiev S. Todorov VV, Manitius J et al. Comparison of the therapeutic effects of epoetin zeta and epoetin alpha in the correction of renal anaemia. Curr. Med. Res. Opin. 24(5), 1407-1415 (2008
13. Gertz B, Kohler E, Kesp P et al. Epoetin theta: efficacy and safety of IV administration in anaemic haemodialysis patients in the maintenance phase in comparison to epoetin beta. Curr. Med. Res. Opin. 26(10), 2393-2402 (2010
14. Tjulandin SA, Bias P, Elsässer R et al. Epoetin theta in anaemic cancer. patients receiving platinum-based chemotherapy: a randomised controlled trial. Arch. Drug Inf. 3(3), 45-53 (2010
15. Tjulandin SA, Bias P, Elsässer R et al. Epoetin theta with a new dosing schedule in anaemic cancer patients receiving nonplatinum-based chemotherapy: a randomised controlled trial. Arch. Drug Inf. 4(3), 33-41 (2011
16. Jelkmann W. Biosimilar epoetins and other "follow-on" biologics: update on the European experiences. Am. J. Hematol. 85(10), 771-780 (2010
17. Dranitsaris G, Amir E, Dorward K. Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations. Drugs 71(12), 1527-1536 (2011
18. Aapro M, Cornes P, Sun D, Abraham I. Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis- stimulating agent to manage chemotherapy-induced anemia in patients with cancer. Ther. Adv. Med. Oncol. 4(3), 95-105 (2012
19. Ludwig H, Aapro M, Bokemeyer C et al. Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study. Eur. J. Cancer 45(9), 1603-1615 (2009
20. Eurostat European statistics. http://epp.uerostat.ec.europa.eu/tgm/table. do?tab=table&language=en&pcode=tps00001&tableSelection= 1&footnotes=yes&labeling=labels&plugin=1
21. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350(23), 2335-2342 (2004
22. Pfreundschuh M, Trumper L, Kloess M et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 104(3), 634-641 (2004
23. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11), 783-792 (2001
24. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur. J. Cancer 46(4), 765-781 (2010
25. Abraham I, MacDonald K. Clinical efficacy and safety of HX575, a biosimilar recombinant human erythropoietin, in the management of anemia. Biosimilars 2, 13-25 (2012
26. Sullivan R, Peppercorn J, Sikora K et al. Delivering affordable cancer care in high-income countries. Lancet Oncol. 12(10), 933-980 (2011
27. Schellekens H, Moors E. Clinical comparability and European biosimilar regulations. Nat. Biotechnol. 28(1), 28-31 (2010
28. Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat. Rev. Drug Discov. 1(6), 457-462 (2002
29. Schellekens H. The first biosimilar epoetin: but how similar is it? Clin. J. Am. Soc. Nephrol. 3(1), 174-178 (2008
30. Casadevall N, Nataf J, Viron B et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 346(7), 469-475 (2002
31. Goldsmith D, Gesualdo L. Biosimilar epoetins in nephrology-where are we now? Eur. Nephrol. 6(1), 21-24 (2012
32. IGES Institute. The competitive role of biosimilars in the German SHI market for pharmaceuticals (2010). www.baselgovernance.org/fileadmin/docs/ Events/Generics-2011/14-Dr.-Joerg-Windisch.pdf
33. IMS Health. Shaping the biosimilars opportunity: a global perspective on the evolving biosimilars landscape (2011). www.imshealth.com/ims/Global/Content/ Home%20Page%20Content/IMS%20News/Biosimilars-Whitepaper.pdf
34. Dalgaard K, Evers M, Santso Da Silva J. Biosimilars seven years on: where are we and what's next? (2013). www.mckinsey.com/?/media/mckinsey/dotcom/ client-service/Pharma%20and%20Medical%20Products/PMP%20NEW/PDFs/ Biosimilars%20Seven%20years%20on-White%20Paper.ashx